Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of sintilimab combined with nab-paclitaxel in platinum-resistant recurrent ovarian, fallopian tube, or primary peritoneal cancer
ChiCTR2000031890Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jan 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and paclitaxel in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal adenocarcinoma (PPC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Tumor markers test and Target lesion. Started Jan 2020; status: recruiting.
02
Drugs
sintilimabpaclitaxel
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal adenocarcinoma (PPC)
Beyond the preview
Go deeper on ChiCTR2000031890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031890.